Evidence map›Paper›PMID 42315255›Full record

SynthesisHemodialysis international. International Symposium on Home Hemodialysis2026

Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Humam Emad Rajha, Richard Shamoon, Ameer Almeshagbeh, Samah Masry, Fadel Alqatati, Baha H Abuajameia, Abdulqadir J Nashwan

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Hemodialysis international. International Symposium on Home Hemodialysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Humam Emad RajhaCollege of Medicine, QU Health, Qatar University, Doha, Qatar.ORCID https://orcid.org/0009-0000-3621-0518
Richard ShamoonNursing and Midwifery Research Department, Hamad Medical Corporation, Doha, Qatar.
Ameer AlmeshagbehDepartment of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA.
Samah MasryNursing and Midwifery Research Department, Hamad Medical Corporation, Doha, Qatar.
Fadel AlqatatiDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Baha H AbuajameiaCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Abdulqadir J NashwanNursing and Midwifery Research Department, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0003-4845-4119

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIron overload in chronic kidney disease contributes to oxidative injury. The role of iron chelators, standard in transfusion-related overload, remains unclear in chronic kidney disease.

aimTo evaluate the efficacy and safety of iron chelators in adults with chronic kidney disease.

methodsA systematic review and meta-analysis followed PRISMA 2020 guidelines. Databases were searched for randomized controlled trials and observational studies reporting on iron indices, hematological parameters, and adverse events.

resultsEleven studies (206 patients) were included. Iron chelation significantly reduced serum ferritin (weighted mean difference [WMD]: -1.48 μg/L; 95% CI: -2.09, -0.87), transferrin (WMD: -10.6 mg/dL; 95% CI: -15.6, -5.61), and serum iron (WMD: -24.2 μg/dL; 95% CI: -42.5, -5.9). Hemoglobin increased (WMD: 1.07 g/dL; 95% CI: 0.20, 1.94). Glucose levels decreased, but lipid parameters were unaffected. Evidence was limited by high heterogeneity and potential bias. Gastrointestinal adverse events were common; serious events were rare.

conclusionIron chelation effectively reduces iron stores and may improve anemia in chronic kidney disease patients. However, the evidence is limited by small sample sizes and heterogeneity. High-quality randomized controlled trials are needed to establish clinical utility and safety before routine use.

Indexed as

Iron Chelating AgentsIron OverloadRenal Insufficiency, ChronicFemaleHumansIron Chelating Agentschronic kidney diseasedeferasiroxdeferoxamineiron chelationiron overloadmeta‐analysissystematic review

Identifiers

PMID42315255
PMCPMC13638482

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.